EviCYP: In Silico Prediction of Cytochrome P450 Substrates Based on Vector Quantization and Evidential Deep Learning
Clinical Snapshot
PICO Framework
| P — Population | Molecular compounds and cytochrome P450 enzyme isoforms (4388 substrates, 2880 nonsubstrates, 3728 pseudonegative samples across 9 CYP isoforms) |
| I — Intervention | EviCYP computational prediction model using evidential deep learning and vector quantization |
| C — Comparator | Traditional computational models for CYP substrate prediction (implied comparison) |
| O — Outcomes | AUROC performance (0.9500), prediction accuracy, uncertainty quantification reliability |
Bottom Line
EviCYP represents a significant advancement in computational prediction of cytochrome P450 substrate specificity, achieving excellent performance (AUROC 0.9500) while providing crucial uncertainty quantification. The model addresses a critical need in drug development by predicting which compounds are likely to be metabolised by specific CYP enzymes, information essential for dosing, drug interactions, and safety assessment. The integration of evidential deep learning allows clinicians and researchers to understand prediction confidence, making the tool more trustworthy for clinical decision-making. While the computational approach shows promise, external validation and real-world implementation studies would strengthen confidence in its clinical utility. For Australian healthcare, this tool could enhance drug safety evaluation processes and support more informed prescribing decisions, particularly for drugs with narrow therapeutic windows or complex interaction profiles.
Key Findings
P Value: Not reported in abstract
Effect Size: AUROC = 0.9500 (excellent discriminative ability)
Primary Outcome: AUROC performance for CYP substrate prediction
Nnt Or Sensitivity: High correlation between uncertainty estimates and classification errors (specific metrics not provided)
Confidence Interval: Not reported in abstract
Clinical Application
Requires computational expertise and infrastructure; may need integration into existing drug development workflows Highly relevant for TGA drug evaluation processes, pharmaceutical industry R&D, and academic drug discovery programs. Could support PBS listing decisions by improving drug safety predictions Pharmaceutical researchers, drug developers, regulatory scientists involved in drug metabolism and safety assessment
Abstract
The accurate identification of cytochrome P450 (CYP) substrates is crucial in drug discovery and safety assessment, as these enzymes mediate the metabolism of most clinical drugs. However, existing computational models are often limited by data quality issues and lack the ability to quantify prediction uncertainty, hindering their reliable application. To address these challenges, we present EviCYP, a novel prediction framework that integrates evidential deep learning with vector quantization (VQ). We first constructed a high-quality data set by curating 4388 substrates and 2880 nonsubstrates from 1629 publications, and supplemented it with 3728 pseudonegative samples, resulting in 10,996 samples spanning nine major CYP isoforms. The EviCYP architecture processes multimodal molecular representations and enzyme sequences through dedicated encoders, compresses features via VQ to reduce redundancy, and employs an evidential layer to output both class probabilities and an uncertainty estimate. On an internal test set, EviCYP achieved an average AUROC of 0.9500. Notably, the model's uncertainty quantification is highly reliable, with high-uncertainty predictions strongly correlating with classification errors. This work provides a robust and trustworthy computational tool for CYP substrate prediction.
References
- 1.Yang, Y., Zhang, Y., Song, W., Zhu, K., Li, X., Tong, M., Liu, G., Li, W., & Tang, Y. (2026). EviCYP: In Silico Prediction of Cytochrome P450 Substrates Based on Vector Quantization and Evidential Deep Learning. Journal of Chemical Information and Modeling. https://doi.org/10.1021/acs.jcim.6c00074
Related Research
CPT: pharmacometrics & systems pharmacology
Structured Schemas for Provenance-Rich, LLM-Assisted QSP Model Calibration
2 Aug 2026
Journal of pharmacokinetics and pharmacodynamics
Diffusion models for virtual populations and pharmacometric simulations
1 Aug 2026
Journal of chemical information and modeling
HyperDC: A Non-Uniform Hypergraph Framework for Dual- and Higher-Order Drug Combination Recommendation Across Diverse Complex Diseases
29 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service